MarginsXMarginsX
Home › Markets › Health Care › KRSA

Korsana Biosciences Inc. (KRSA)

KRSA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$32.68
+3.25% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$2.1M
+3.7% on 2024
Net income · 2025
-$3.5M
-170.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1755237/000119312526132193/0001193125-26-132193-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerKRSA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001755237
SEC industry codePharmaceutical Preparations
Incorporated inMA

Financials · 2025

LineValue
Revenue$2.1M
Net income-$3.5M
Operating income-$5.0M
Net margin-170.1%
Operating margin-239.8%
Revenue growth+3.7%
Cash$3.2M
Total assets$10.0M
P/E (computed)Net income was not positive
P/S (computed)717.6×

Warning signs

Cash runway
133.7 months
$456.2M cash at September 30, 2026
Share count, 1 year
+8021.4%
2025-11-10 to 2026-11-02 · +12937.9% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"Some of the more significant risks and uncertainties we face include the following: We will need to raise additional capital, and if we are unable to do so when needed, that could raise substantial doubt about our ability to continue as a going concern;"
10-Q 2026-11-05
Cash and burn$456.2M cash; operating cash flow -$10.2M a quarter.Report 2026-09-30
Shares outstanding45,541,358 (2026-11-02); 3,925,314 a year earlier; 2,445,096 three years earlier. 1y figure adjusted for splits (1-for-7 overall); 3y figure adjusted for splits (1-for-7 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-7 on 2026-09-09Source 2026-09-09
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-04-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$46.4M-$46.8M$456.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
$0-$17.4M-$1.4M$1.4MNo debt tags$1.9M10-Q 2026-08-04
Q1 2026
2026-03-31
$0-$13.5M-$1.2M$2.8MNo debt tags$2.0M10-Q 2026-05-12
Q4 2025
2025-12-31
$1.0M$18.4M$8.5M$154.1MNo debt tags$2.1M10-K 2026-03-30
Q3 2025
2025-09-30
$875K-$21.7M-$10.3M$4.6MNo debt tags$2.9M10-Q 2025-11-12
Q2 2025
2025-06-30
$93K-$152K-$503K$3.0MNo debt tags$2.2M10-Q 2026-08-04
Q1 2025
2025-03-31
$81K-$73K-$968K$3.6MNo debt tags$2.1M10-Q 2026-05-12
Q4 2024
2024-12-31
$1.8M$530K$360K$3.2MNo debt tags$2.0M10-K 2026-03-30

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-07-24
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEF 14A2026-10-15

Source: SEC EDGAR submissions feed, 397 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.9%
1 month-0.0%
3 months+15.6%
Year to date+256.0%
1 year+214.0%
From 52-week high-29.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
PCRXPacira BioSciences Inc.$36.48+0.05%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
NBTXNanobiotix S.A.$28.54-6.90%$1.5B
QUREuniQure N.V.$21.88-8.11%$1.5B
PGENPrecigen Inc.$4.30-5.29%$1.5B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier